BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 19021723)

  • 1. Delayed complete remission in a patient with multiple myeloma.
    Ria R; Vacca A; Mangialardi G; Dammacco F
    Eur J Clin Invest; 2008 Dec; 38(12):966-8. PubMed ID: 19021723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.
    Orlowski RZ; Nagler A; Sonneveld P; Bladé J; Hajek R; Spencer A; San Miguel J; Robak T; Dmoszynska A; Horvath N; Spicka I; Sutherland HJ; Suvorov AN; Zhuang SH; Parekh T; Xiu L; Yuan Z; Rackoff W; Harousseau JL
    J Clin Oncol; 2007 Sep; 25(25):3892-901. PubMed ID: 17679727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extended follow-up of outcome measures in multiple myeloma patients treated on a phase I study with bortezomib and pegylated liposomal doxorubicin.
    Biehn SE; Moore DT; Voorhees PM; Garcia RA; Lehman MJ; Dees EC; Orlowski RZ
    Ann Hematol; 2007 Mar; 86(3):211-6. PubMed ID: 17146676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pegylated liposomal doxorubicin in combination with dexamethasone and bortezomib (VMD) or lenalidomide (RMD) in multiple myeloma pretreated patients.
    Buda G; Orciuolo E; Galimberti S; Pelosini M; Petrini M
    Ann Hematol; 2011 Sep; 90(9):1115-6. PubMed ID: 21181162
    [No Abstract]   [Full Text] [Related]  

  • 5. Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma.
    Jakubowiak AJ; Kendall T; Al-Zoubi A; Khaled Y; Mineishi S; Ahmed A; Campagnaro E; Brozo C; Braun T; Talpaz M; Kaminski MS
    J Clin Oncol; 2009 Oct; 27(30):5015-22. PubMed ID: 19738129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy.
    Sonneveld P; Hajek R; Nagler A; Spencer A; Bladé J; Robak T; Zhuang SH; Harousseau JL; Orlowski RZ;
    Cancer; 2008 Apr; 112(7):1529-37. PubMed ID: 18300257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
    Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y
    Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bortezomib in combination with pegylated liposomal doxorubicin for the treatment of multiple myeloma.
    Manochakian R; Miller KC; Chanan-Khan AA
    Clin Lymphoma Myeloma; 2007 Jan; 7(4):266-71. PubMed ID: 17324333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. VAD combination chemotherapy followed by bortezomib may be an effective treatment in secondary plasma cell leukemia.
    Ataergin S; Arpaci F; Kaya A; Cetin T; Gunhan O
    Am J Hematol; 2006 Dec; 81(12):987-8. PubMed ID: 16888783
    [No Abstract]   [Full Text] [Related]  

  • 10. Bortezomib in combination with dexamethasone for relapsed multiple myeloma.
    Kropff MH; Bisping G; Wenning D; Volpert S; Tchinda J; Berdel WE; Kienast J
    Leuk Res; 2005 May; 29(5):587-90. PubMed ID: 15755512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: efficacy and safety in patients with renal function impairment.
    Bladé J; Sonneveld P; San Miguel JF; Sutherland HJ; Hajek R; Nagler A; Spencer A; Robak T; Cibeira MT; Zhuang SH; Harousseau JL; Orlowski RZ;
    Clin Lymphoma Myeloma; 2008 Dec; 8(6):352-5. PubMed ID: 19064400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Weekly bortezomib, pegylated liposomal doxorubicin, and dexamethasone is a safe and effective therapy for elderly patients with relapsed/refractory multiple myeloma.
    Gozzetti A; Fabbri A; Oliva S; Marchini E; Bocchia M; Defina M; Lauria F
    Clin Lymphoma Myeloma Leuk; 2010 Feb; 10(1):68-72. PubMed ID: 20223732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Very good partial response and long time to progression by short-term bortezomib plus dexamethasone therapy for a patient with relapsed and refractory multiple myeloma-a case report].
    Fukushima T; Iwao H; Nakajima A; Miki M; Sakai T; Sawaki T; Tanaka M; Masaki Y; Hirose Y; Umehara H
    Gan To Kagaku Ryoho; 2009 Aug; 36(8):1387-9. PubMed ID: 19692786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma.
    Ciolli S; Leoni F; Casini C; Breschi C; Santini V; Bosi A
    Br J Haematol; 2008 Jun; 141(6):814-9. PubMed ID: 18410447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up.
    Popat R; Oakervee HE; Hallam S; Curry N; Odeh L; Foot N; Esseltine DL; Drake M; Morris C; Cavenagh JD
    Br J Haematol; 2008 May; 141(4):512-6. PubMed ID: 18371113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trial.
    Chanan-Khan A; Miller KC; Musial L; Padmanabhan S; Yu J; Ailawadhi S; Sher T; Mohr A; Bernstein ZP; Barcos M; Patel M; Iancu D; Lee K; Czuczman MS
    Leuk Lymphoma; 2009 Jul; 50(7):1096-101. PubMed ID: 19479618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib.
    Sood R; Carloss H; Kerr R; Lopez J; Lee M; Druck M; Walters IB; Noga SJ
    Am J Hematol; 2009 Oct; 84(10):657-60. PubMed ID: 19731393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid complete remission in multiple myeloma with bortezomib/thalidomide/dexamethasone combination therapy following development of tumor lysis syndrome.
    Chim CS
    Cancer Chemother Pharmacol; 2008 Jun; 62(1):181-2. PubMed ID: 17846773
    [No Abstract]   [Full Text] [Related]  

  • 19. Cutaneous involvement in multiple myeloma and bortezomib.
    Siniscalchi A; Fratoni S; Santeusanio G; Del Poeta G; de Fabritiis P; Caravita T
    Ann Hematol; 2009 Nov; 88(11):1137-9. PubMed ID: 19259673
    [No Abstract]   [Full Text] [Related]  

  • 20. Bortezomib in multiple myeloma: treatment and retreatment. A single center experience.
    Warzocha K; Kraj M; Pogłód R; Kwaśniak B
    Acta Pol Pharm; 2008; 65(6):753-6. PubMed ID: 19172860
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.